



Issue of Securities Following General Meeting Approval

Melbourne, Australia, 13 December 2024 – InhaleRx Ltd (ASX: IRX), (**‘IRX’ or ‘the Company’**) an Australian healthcare company developing unique inhaled drug-device products to address unmet medical needs in the pain management and mental health sectors, advises that it has today issued securities for accrued director fees and options to Clendon Biotech Capital Pty Ltd, pursuant to shareholder approval at the General Meeting held 28 November 2024.

The requisite ASX online announcements will be separately lodged.

Authorised by the Board of Directors.

For further information:

www.inhalerx.com.au

James Barrie, Company Secretary

Phone +61 3 8678 4091

About InhaleRx Limited (ASX: IRX) – www.inhalerx.com.au

InhaleRx Limited is an Australian healthcare company which is developing unique medicinal drug-device products to address unmet medical needs in pain management and mental health sectors.

The overarching goal is to pursue U.S. FDA approval and registration using rapid and cost-effective regulatory pathways, such as 505(b)(2).

There is a significant economic opportunity for IRX and the Company’s shareholders. The first medical indications under investigation are Breakthrough Cancer Pain (**‘BTcP’**) and Panic Disorder (**‘PD’**), both of which currently have limited safe and effective treatment options.

IRX holds an innovation patent and provisional patents for the nominated indications and the Company plans to continue to strengthen this position.